Voyager Therapeutics (NASDAQ:VYGR) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 1 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $26.25, with a high estimate of $30.00 and a low estimate of $15.00. This current average has decreased by 12.5% from the previous average price target of $30.00.
Exploring Analyst Ratings: An In-Depth Overview
The standing of Voyager Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Patrick Trucchio | HC Wainwright & Co. | Maintains | Buy | $30.00 | $30.00 |
| Patrick Trucchio | HC Wainwright & Co. | Maintains | Buy | $30.00 | $30.00 |
| Lili Nsongo | Leerink Partners | Announces | Outperform | $15.00 | - |
| Patrick Trucchio | HC Wainwright & Co. | Maintains | Buy | $30.00 | $30.00 |
Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Voyager Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company. Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Voyager Therapeutics compared to the broader market. Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Voyager Therapeutics's stock. This examination reveals shifts in analysts' expectations over time.
Capture valuable insights into Voyager Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Voyager Therapeutics analyst ratings.
If you are interested in following small-capstock newsand performance you can start by tracking it here.
Get to Know Voyager Therapeutics Better
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Voyager Therapeutics's Financial Performance
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Positive Revenue Trend: Examining Voyager Therapeutics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 509.48% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -34.29%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Voyager Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -3.0%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Voyager Therapeutics's ROA excels beyond industry benchmarks, reaching -2.24%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.14, Voyager Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Significance of Analyst Ratings Explained
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Latest Ratings for VYGR
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2021 | Chardan Capital | Maintains | Neutral | |
| Oct 2021 | Baird | Upgrades | Neutral | Outperform |
| Jun 2021 | Compass Point | Initiates Coverage On | Buy |
View More Analyst Ratings for VYGR
View the Latest Analyst Ratings
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
